|

|
|

|
|
¾È³çÇϽʴϱî?
µ¹¾Æ¿À´Â 2013³â º½À» ¸Â¾Æ, ´ëÇѹé½ÅÇÐȸÀÌ 3¹øÂ° Çмú´ëȸ·Î Ãá°ÔÇмú´ëȸ¸¦ °³ÃÖÇÕ´Ï´Ù. Áö³ Ãá°è, Ãß°èÇмú´ëȸµµ ¿©·¯ ȸ¿ø´Ôµé²²¼ Àû±ØÀûÀ¸·Î Âü¿©ÇØÁֽðí, ½ÉÆ÷Áö¾ö ÁÖÁ¦¿Í ¹ßÇ¥ ³»¿ë¿¡ ´ëÇØ¼µµ ¾ÆÁÖ ±àÁ¤ÀûÀ¸·Î Æò°¡ÇØ Áּż ¸¹Àº ÈûÀÌ µÇ¾ú½À´Ï´Ù.
CEVR 2¹øÂ° ¹ßÇົÀÌ 1¿ù¿¡ ÀμâµÇ¾ú°í, ¿©·¯ ȸ¿ø´Ôµé²² Àü´ÞµÇ¾úÀ» ÁÙ ¾Ð´Ï´Ù. ¿Ã ÇØ´Â ´ëÇѹé½ÅÇÐȸ°¡ ±¹³» ¿©·¯ ¹é½Å°ü·Ã Àü¹®°¡µé¿¡°Ô Á» ´õ Ä£¼÷ÇÑ ¸ðÀÓÀ¸·Î ´Ù°¡°¡°í, ±Û·Î¹úÇÑ ³×Æ®¿öÅ©¸¦ ¸¸µé¾î°¡´Â ½Ã°£ÀÌ µÉ ¼ö ÀÖµµ·Ï ÇϰڽÀ´Ï´Ù.
À̹ø Ãá°èÇмú´ëȸ¿¡¼´Â ½ÉÆ÷Áö¾ö ³× °¡ÁöÀÇ ÁÖÁ¦¿Í Ưº° °¿¬À» ¸¶·ÃÇÏ¿´½À´Ï´Ù. Àμö°øÅë°¨¿°º´ÀÇ ¼Ò°³¿Í ¹é½Å»ç¿ë, ¹é½ÅÀÇ °³¹ß Áß ¹é½ÅÀÇ Á¢Á¾¹ý¿¡ °üÇÑ ¿¬±¸¿Í ÀÓ»óÀû¿ë, ±×¸®°í »ç¶÷ ¹é½ÅÀÇ ÃÖ±Ù °¡ÀÌµå º¯È¿Í °³¹ß ÇöȲÀ» ¼Ò°³Çϰí, ºñ°¨¿°¼º ¹é½ÅÀ¸·Î ¾Ï¹é½ÅÀÇ °³¹ß¿¡ °üÇÑ ÃֽŠÁö°ßÀ» Á¢ÇÏ½Ç ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, Ưº° °¿¬À» ÅëÇØ µ¿°æ´ë Kiyono Hiroshi¹Ú»ç¸¦ ÃÊûÇÏ¿© Á¡¸·¸é¿ª¿¡ °üÇÑ ¼¼°èÀûÀÎ È帧À» ´À³¢½Ç ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.
±â²¨ÀÌ Æ¯º° °¿¬À» ¸Ã¾ÆÁֽŠKiyono Hiroshi ±³¼ö´Ô°ú ½ÉÆ÷Áö¾ö ¹ßÇ¥ÀÚ·Î Âü¿©ÇØÁÖ½Ç ¿©·¯ ¼±»ý´Ôµé²² Áø½ÉÀ¸·Î °¨»ç¸¦ µå¸³´Ï´Ù.
À̹ø Çмú´ëȸ°¡ ȸ¿ø ¿©·¯ºÐµéÀÇ Àû±ØÀûÀÎ Âü¿©¿Í ÇÔ²² Ȱ¹ßÇÑ Åä·ÐÀÇ ÀåÀÌ µÇ¸®¶ó È®½ÅÇÕ´Ï´Ù.
°¨»çÇÕ´Ï´Ù. |
|
´ëÇѹé½ÅÇÐȸ ȸÀå ±è Á¤ ¼ö ¿Ã¸² | |
|

|
|
09:00 |
°³È¸»ç |
±èÁ¤¼ö ȸÀå |
|
9:00-10:30 |
Session I ; Vaccine for Zoonosis |
|
ÁÂÀå: |
ÀÌÁߺ¹(°Ç±¹´ë) À¯ÇÑ»ó(¼¿ï´ë) | |
|
|
Characteristics of hepatitis E virus and development of the vaccine |
ÃÖÀμö(°Ç±¹´ë) |
|
|
»ì¸ð³Ú¶ó¹é½Å °³¹ßÇöȲ ¹× Àü¸Á |
ÀÌÈñ¼ö (³ó¸²¼ö»ê°Ë¿ªº»ºÎ) |
|
|
Zoonotic and vector-borne viral diseases: transmission and epidemiology |
°íÀ±¿µ (Çѱ¹ÈÇבּ¸¿ø) |
|
10:30-10:40 |
Coffee break |
|
10:40-12:10 |
Session II ; Vaccine delivery; Bench to bedside |
|
ÁÂÀå: |
ÀÌÁØÇà(Àü³²´ë) ¼º¹é¸°(¿¬¼¼´ë) | |
|
|
Microneedle patches for improved influenza vaccination |
±èÀ¯Ãµ(Ä«À̽ºÆ®) |
|
|
Eye-drop vaccination induce systemic and mucosal immune response against influenza virus |
¼°æ·ü(¿¬¼¼´ë) |
|
|
papillomavirus-associated diseases: progresses in clinical and animal studies |
½ÅÁ¤ÀÓ(°¿ø´ë) |
|
12:10-13:10 |
·±Ãµ½ÉÆ÷Áö¿ò |
|
13:10-13:50 |
Invited lecture |
|
|
|
Forward Motion in the Development of Ideal Mucosal Vaccine |
Kiyono Hiroshi (µ¿°æ´ë) |
|
13:50-15:20 |
Session III ; Human vaccines |
|
ÁÂÀå: |
°ÁøÇÑ(°¡Å縯´ë) ¿À¸íµ·(¼¿ï´ë) | |
|
|
Changes in PPV guidelines |
Á¤ÈñÁø(°í·Á´ë) |
|
|
Vaccine storage and management |
ÀÌÅÃÁø(ºÐ´çÂ÷º´¿ø) |
|
|
Tuberculosis vaccine |
·ù¼º¿ø(°áÇÙ¿¬±¸¿ø) |
|
15:20-15:30 |
Coffee break |
|
15:30-17:00 |
Session IV ; Immune cell-based Therapeutic Cancer Vaccine |
|
ÁÂÀå: |
¹è¿ë¼ö(¼º±Õ°ü´ë) ±èâÈÖ (¼øÃµÇâÀÇ´ë) | |
|
|
Dendritic cell therapy against multiple myeloma |
ÀÌÁ¦Áß (Àü³²´ë) |
|
|
Core-shell nanoparticles for anti-cancer DC immunotherapy |
¼º½Â¿ë (¼¿ï´ë) |
|
|
Strategies to enhance CEA specific antitumor immunity in murine model |
±èÅÂ±Ô (°¡Å縯´ë) |
|
17:00 |
Æóȸ»ç |
±èÁ¤¼ö ȸÀå | |
|

|
|
»çÀüµî·Ï ±â°£: 2013³â 2¿ù 28ÀÏ(±Ý)
|
|
(Á¢¼ö ¸¶°¨ÀÏ ÀÚÁ¤ÀÌ Áö³ª¸é ÀÎÅÍ³Ý Á¢¼ö âÀº ȨÆäÀÌÁö¿¡¼ Æó¼âµÇ¿À´Ï Á¢¼ö ¸¶°¨ ÀÏÀ» ²À ÁöÄÑÁֽʽÿÀ.) |
|
»çÀüµî·Ï ¹æ¹ý
|
|
¡æ |
ÇÐȸ ȨÆäÀÌÁöÀÇ ÇмúÇà»ç ÆäÀÌÁö '»çÀüµî·Ï' ¸Þ´º¸¦ ¸¶¿ì½º·Î Ŭ¸¯ÇÕ´Ï´Ù. |
|
¡æ |
»çÀüµî·Ï ÀÛ¼º¿ä·É¿¡ µû¶ó ÀÔ·ÂÇÏ¿© »çÀüµî·Ï ½ÅûÀÌ Á¢¼ö µÇ¸é µî·ÏÈ®ÀÎ À̸ÞÀÏÀ» º¸³»µå¸®¸ç, ÇÐȸ¿¡¼ µî·Ïºñ ÀÔ±Ý ¿©ºÎ¸¦ È®ÀÎ ÀÌ»óÀÌ ¾øÀ» °æ¿ì ÀÔ±Ý È®ÀÎ À̸ÞÀÏÀ» ¹ß¼ÛÇÕ´Ï´Ù. |
|
¡æ |
»çÀüµî·Ï ½Ã ÀÎÅÍ³Ý »çÀüµî·Ï¸¸ ÇϽðí, µî·Ïºñ ¼Û±ÝÀ» ÇÏÁö ¾ÊÀ» °æ¿ì¿Í µî·Ïºñ¸¸ ¼Û±ÝÇϰí ÀÎÅÍ³Ý »çÀüµî·ÏÀ» ÇÏÁö ¾ÊÀ» °æ¿ì »çÀüµî·ÏÀÌ µÇÁö ¾Ê½À´Ï´Ù. ¹Ýµå½Ã ¿Â¶óÀÎ »çÀüµî·Ï ½Åû ¹× µî·Ïºñ ÀÔ±ÝÀ» ¸ðµÎ ÇÏ¼Å¾ß ÇÕ´Ï´Ù. |
|
¡æ |
µî·Ïºñ °áÀç ¹æ¹ý : ½Å¿ëÄ«µå ¹× ¿Â¶óÀÎÀԱݽà ¹Þ½À´Ï´Ù. ¿Â¶óÀÎÀԱݽà ¼Û±ÝÀÎÀ» Á¤È®È÷ Àû¾îÁֽʽÿÀ. |
|
* |
»çÀüµî·Ï¸¶°¨ÀÌÈÄ(2¿ù 28ÀÏ) ȯºÒÀÌ ºÒ°¡ÇÕ´Ï´Ù.(Çà»ç´çÀÏ ¹× Çà»ç Á¾·á ÈÄ È¯ºÒ ºÒ°¡) | |
|
»çÀüµî·Ï
|
|
±¸ ºÐ |
±¸ ºÐ |
»çÀüµî·Ïºñ |
|
ȸ¿ø |
Àü°øÀÇ, ´ëÇÐ, ´ëÇпø ÀçÇлý, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø |
2¸¸¿ø |
|
ÀüÀÓÀÇ, ¹Ú»ç±Þ ÀÌ»ó ¼±ÀÓ ¹× Ã¥ÀÓ ¿¬±¸ÀÚ |
3¸¸¿ø |
|
ºñȸ¿ø |
ºñȸ¿ø |
5¸¸¿ø | |
|
ÇöÀåµî·Ï
|
|
±¸ ºÐ |
±¸ ºÐ |
ÇöÀåµî·Ïºñ |
|
ȸ¿ø |
Àü°øÀÇ, ´ëÇÐ, ´ëÇпø ÀçÇлý, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø |
4¸¸¿ø |
|
ÀüÀÓÀÇ, ¹Ú»ç±Þ ÀÌ»ó ¼±ÀÓ ¹× Ã¥ÀÓ ¿¬±¸ÀÚ |
5¸¸¿ø |
|
ºñȸ¿ø |
ºñȸ¿ø |
7¸¸¿ø | | |
|

| |